Regencell Bioscience is an early-stage Hong Kong bioscience company developing traditional Chinese medicine (TCM) treatments for neurocognitive conditions, notably ADHD and autism spectrum disorder. It works on standardized liquid TCM formula candidates aimed at mild to severe cases, with initial focus on Hong Kong before broader markets. Commercial revenue remains minimal as the business is still primarily research- and development-driven.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 0 | — | -7.5 | — |
| 2023 | 0 | — | -5.9 | — |
| 2024 | 0 | — | -4.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Icahn Enterprises L.P. (IEP), Insight Enterprises, Inc. (NSIT), Construction Partners, Inc. (ROAD), Dave Inc. (DAVE), Erasca, Inc. (ERAS), Option Care Health, Inc. (OPCH)